Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions By Ogkologos - June 23, 2026 50 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the WU-KONG28 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... November 26, 2019 Initial Results of the CanScreen5, an Authentic Data Repository for Cancer... May 4, 2023 Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... November 9, 2020 Eight Factors May Link Disparities in Cancer Death Rates and Income November 8, 2018 Load more HOT NEWS Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early... A Cancer Revolution comes to Manchester: Patrick’s review Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma
